Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-37553 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-EGFR (Tyr1197) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control for Western blot is HUVEC cells; suggested positive control for IHC is human breast carcinoma.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH.
Integrated analyses of murine breast cancer models reveal critical parallels with human disease.
Swiatnicki MR, Rennhack JP, Ortiz MMO, Hollern DP, Perry AV, Kubiak R, Riveria Riveria SM, O'Reilly S, Andrechek ER
PLoS genetics 2022 Sep;18(9):e1010362
PLoS genetics 2022 Sep;18(9):e1010362
Integrated analyses of murine breast cancer models reveal critical parallels with human disease.
Rennhack JP, To B, Swiatnicki M, Dulak C, Ogrodzinski MP, Zhang Y, Li C, Bylett E, Ross C, Szczepanek K, Hanrahan W, Jayatissa M, Lunt SY, Hunter K, Andrechek ER
Nature communications 2019 Jul 22;10(1):3261
Nature communications 2019 Jul 22;10(1):3261
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of extracts from HUVEC cells, untreated or treated with EGF, using EGFR (pTyr1197) polyclonal antibody (Product # PA5-37553).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-EGFR (Tyr1197) in paraffin-embedded Human breast carcinoma tissue using Phospho-EGFR (Tyr1197) Polyclonal Antibody (Product # PA5-37553) (left) or the same antibody preincubated with blocking peptide (right).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 10.1371/journal.pgen.1010362.g004 Fig 4 PTPRH mutant cell lines respond to TKI osimertinib. Pooled PTPRH KO cells have increased proliferation, and PTPRH mutant cell lines respond to osimertinib. A) Western blotting confirms increased p-EGFR at tyrosine 1197 within pooled KO cells compared to WT cells. B) Cellular growth curves show increased growth in PTPRH pooled KO cells as compared to WT cells. C) MTT assays completed with H23 WT and H23 PTPRH pooled KO cells show increased proliferation. D) Two PTPRH mutant cell lines (WT for EGFR) from human non-small cell lung cancer tumors show response to the TKI osimertinib in vitro . E) Treatment plan for in vivo treatment of H2228 PTPRH mutant cell line. Either H1975 (L858R EGFR mutant) or H2228 (Q887P PTPRH mutant) cells were injected into the left flank of nude mice. Mice were then randomized into two treatment groups, vehicle control or osimertinib. H1975 mice were treated with 25 mg/kg of osimertinib and H2228 injected mice were treated with either 25 mg/kg or 50 mg/kg of osimertinib. F) in vivo drug curve showing response to osimertinib of H1975 EGFR mutant injected mice. G) in vivo drug curve showing response to osimertinib of H2228 PTPRH mutant injected mice.
